DDInter1094 DDInter1658
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Lorlatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Betrixaban
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide
Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Lorlatinib may lead to a major life threatening interaction when taken with Venetoclax
Lorlatinib may lead to a major life threatening interaction when taken with Lurbinectedin